BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780)
South Korea · Delayed Price · Currency is KRW 5,270.00
+10.00 (0.19%)
Feb 5, 2026, 3:30 PM KST
BCWORLD PHARM. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 77,044 | 74,814 | 75,111 | 72,703 | 62,079 | 57,030 |
Other Revenue | -0 | -0 | - | -0 | - | -0 |
| 77,044 | 74,814 | 75,111 | 72,703 | 62,079 | 57,030 | |
Revenue Growth (YoY) | 5.71% | -0.40% | 3.31% | 17.11% | 8.85% | 10.74% |
Cost of Revenue | 45,850 | 46,803 | 43,234 | 45,497 | 42,149 | 36,679 |
Gross Profit | 31,194 | 28,012 | 31,876 | 27,206 | 19,931 | 20,351 |
Selling, General & Admin | 17,295 | 15,945 | 16,127 | 21,261 | 11,662 | 10,850 |
Research & Development | 8,666 | 7,779 | 6,141 | 770.66 | 9,298 | 10,951 |
Amortization of Goodwill & Intangibles | 341.82 | 325.26 | 287.74 | 235.2 | 110.4 | 126.82 |
Other Operating Expenses | 302.82 | 302.2 | 132.24 | 58.84 | 200.34 | 219.58 |
Operating Expenses | 27,951 | 26,512 | 25,511 | 25,344 | 21,464 | 22,448 |
Operating Income | 3,243 | 1,500 | 6,365 | 1,862 | -1,534 | -2,096 |
Interest Expense | -4,284 | -4,760 | -5,234 | -3,792 | -2,169 | -2,418 |
Interest & Investment Income | 190.48 | 207.91 | 187.98 | 129.42 | 180.31 | 221.69 |
Currency Exchange Gain (Loss) | -119.91 | 54.35 | 110.63 | 376.05 | 317.28 | -367.75 |
Other Non Operating Income (Expenses) | -358.55 | 240.24 | -285.96 | 501.3 | 498.41 | 1,634 |
EBT Excluding Unusual Items | -1,329 | -2,758 | 1,144 | -923.13 | -2,707 | -3,026 |
Gain (Loss) on Sale of Investments | -109.25 | -28.94 | 13.42 | -535.17 | -229.14 | - |
Gain (Loss) on Sale of Assets | -135.1 | 20.77 | 48.91 | -0.32 | -0 | 198.74 |
Asset Writedown | - | - | - | -64.29 | - | -2.36 |
Pretax Income | -1,573 | -2,766 | 1,206 | -1,523 | -2,936 | -2,830 |
Income Tax Expense | 592.94 | 550.12 | -1,686 | -1,583 | 42.06 | -635.66 |
Earnings From Continuing Operations | -2,166 | -3,316 | 2,892 | 59.78 | -2,978 | -2,194 |
Minority Interest in Earnings | -1,598 | -1,116 | -258.52 | 221.52 | 1,135 | 614.15 |
Net Income | -3,765 | -4,433 | 2,634 | 281.3 | -1,843 | -1,580 |
Net Income to Common | -3,765 | -4,433 | 2,634 | 281.3 | -1,843 | -1,580 |
Net Income Growth | - | - | 836.31% | - | - | - |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Change (YoY) | 0.21% | - | -0.98% | -0.19% | 0.35% | -0.73% |
EPS (Basic) | -368.19 | -434.11 | 257.95 | 27.28 | -178.39 | -153.46 |
EPS (Diluted) | -368.19 | -434.11 | 257.95 | 27.28 | -178.39 | -153.46 |
EPS Growth | - | - | 845.59% | - | - | - |
Free Cash Flow | 626.48 | 1,644 | 8,361 | 666.21 | -18,064 | -13,288 |
Free Cash Flow Per Share | 61.27 | 161.05 | 818.82 | 64.61 | -1748.42 | -1290.57 |
Dividend Per Share | 82.645 | 82.645 | - | - | - | 82.645 |
Gross Margin | 40.49% | 37.44% | 42.44% | 37.42% | 32.10% | 35.69% |
Operating Margin | 4.21% | 2.00% | 8.47% | 2.56% | -2.47% | -3.68% |
Profit Margin | -4.89% | -5.92% | 3.51% | 0.39% | -2.97% | -2.77% |
Free Cash Flow Margin | 0.81% | 2.20% | 11.13% | 0.92% | -29.10% | -23.30% |
EBITDA | 11,091 | 9,194 | 13,835 | 9,070 | 3,641 | 2,473 |
EBITDA Margin | 14.40% | 12.29% | 18.42% | 12.48% | 5.86% | 4.34% |
D&A For EBITDA | 7,848 | 7,694 | 7,470 | 7,208 | 5,174 | 4,569 |
EBIT | 3,243 | 1,500 | 6,365 | 1,862 | -1,534 | -2,096 |
EBIT Margin | 4.21% | 2.00% | 8.47% | 2.56% | -2.47% | -3.68% |
Advertising Expenses | - | 922.8 | 1,274 | 1,505 | 1,085 | 728.19 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.